A phase II study of gemcitabine (GEMZAR) and irinotecan (CPT-11) in previously untreated patients with measurable disease with unknown primary carcinoma

Trial Profile

A phase II study of gemcitabine (GEMZAR) and irinotecan (CPT-11) in previously untreated patients with measurable disease with unknown primary carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Gemcitabine (Primary) ; Irinotecan (Primary)
  • Indications Cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jun 2012 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
    • 10 Mar 2009 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
    • 06 May 2008 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top